FDA approves NGS blood test oversized panel, a new milestone in liquid biopsy

On May 20, 2026, Guardant Health, a global leader in liquid biopsy, announced that the U.S. Food and Drug Administration (FDA) officially approved the launch of its newly upgraded Guardant360® Liquid CDx test. This approval is not simply an ordinary one; instead, it symbolizes a milestone that thoroughly revises the rules.

On May 20, 2026, Guardant Health, a global liquid biopsy giant, announced that the U.S. Food and Drug Administration (FDA) officially approved Guardant Health's new - generation liquid biopsy product, Guardant360® Liquid CDx, for the market. This detection product is not only the largest liquid biopsy panel approved by the FDA to date, but its genomic detection coverage is 100 - fold greater than that of the previously approved Guardant360 CDx version. Simultaneously, it has, for the first time, integrated two dimensions of tumor molecular information, namely genomics and epigenomics, into blood testing.

Press release from Guardant Health's official website

This signifies the formal transition of blood - based Comprehensive Genomic Profiling (CGP) from an “alternative tool” to the “preferred entry point” of the cancer precision diagnosis and treatment system. As stated by Helmy Eltoukhy, the chairman and co - CEO of Guardant Health: "With the FDA's approval of the new - generation Guardant360 LiquidCDx, cancer diagnosis and treatment have officially entered a new era. Genomics, epigenomics, advanced artificial intelligence, and the testing experience from over one million patients converge. Through a simple blood draw, it can present a more comprehensive and informative panorama of cancer molecules for clinical application."

Guardant360® Liquid CDxproduct Information

PART 1

Core Clinical Advantages of Multi - Omics Liquid Biopsy

1. Non - invasive and Convenient, Suitable for Patients Unsuitable for Biopsy

Traditional tissue biopsy necessitates the acquisition of tumor tissue via puncture, surgery, etc. It is characterized by high trauma, a high risk of complications (e.g., bleeding, infection), and a sampling failure rate ranging from 15% to 20%. It is particularly inappropriate for patients with bone metastases, deep - seated tumors, advanced and frail patients, and children. The non - invasive, safe, and repeatable sampling features of liquid biopsy can address the clinical challenges associated with tissue biopsy.

2. Overcoming Tumor Heterogeneity and Reflecting the Overall Picture of Tumors throughout the Body

Tumor heterogeneity represents the core bottleneck in precision diagnosis and treatment. There are substantial differences in molecular characteristics within the same tumor and among different metastases. Single - point tissue biopsy can only reflect local tumor information, which is prone to result in missed detection, mutations, and misjudgment of drug - resistance mechanisms. Liquid biopsy detects the circulating tumor DNA (ctDNA) released into the blood by tumors throughout the body. It can integrate the molecular information of all tumor lesions, truly reflecting the heterogeneity of tumors throughout the body and avoiding sampling bias.

3. Panoramic Analysis of Multi - Omics, Breaking through the Limitations of Single Omics Detection

Traditional single - omics (genome - only) assays can only identify approximately 60% of clinically relevant interventional targets. A large number of tumor drivers and drug - resistance mechanisms caused by epigenetic regulatory abnormalities (e.g., methylation) cannot be recognized. In contrast, multi - omics liquid biopsy can identify an additional 25% - 30% of epigenetic driving targets, significantly enhancing the target detection rate and providing more patients with opportunities for targeted treatment.

4. Real - time Dynamic Monitoring, Early Warning of Drug Resistance and Recurrence

Patients with advanced tumors are prone to develop drug - resistant mutations during treatment. Traditional tissue biopsy does not allow for repeated sampling and monitoring. Drug resistance is often detected only after disease progression, resulting in missed opportunities for intervention. Liquid biopsy enables repeated blood sampling for testing every 4 - 6 weeks, allowing for real - time tracking of changes in the mutation spectrum of ctDNA. It can detect drug - resistant mutations 3 - 6 months in advance. Simultaneously, it can monitor minimal residual disease (MRD) and provide an early warning of recurrence 6 - 12 months in advance, thereby buying valuable time for clinical intervention.

PART 2

The future holds promising prospects.

The CDx approval of Guardant360 Liquid CDx has achieved three key breakthroughs at the technical level: from limited genes to panoramic coverage, from single - dimensional to multi - omics fusion, and from weeks of waiting to results within a week. At the industrial level, it marks the comprehensive upgrade of liquid biopsy from an “auxiliary tool” to a “core of decision - making”. When comprehensive molecular information that used to require multiple tissue biopsies can be obtained (or even cannot be obtained) with a single blood draw, the decision - making paradigm of clinical diagnosis and treatment will undergo fundamental changes.

However, we also need to clearly realize that technological breakthroughs are only the first step in the popularization of precision medicine. The wide clinical application of large - panel liquid biopsy still faces multiple challenges: the affordability of testing costs, the medical coverage of medical insurance reimbursement, the ability of clinicians to understand and interpret multi - group reports, the establishment of testing standardization and quality control systems, and the proper response to data privacy and ethical issues.

As Helmy Eltoukhy posited, "The upper bound of precision oncology hinges upon the comprehensiveness of the information available to clinicians at the decision - making juncture." From this vantage point, the approval of Guardant360 Liquid CDx is not merely a triumph for the Guardant Health consortium but a substantial stride for the entire precision oncology domain on the path towards the ultimate objective of "furnishing every physician with the appropriate information at the opportune moment to render the correct decision."

References

https://investors.guardanthealth.com/press-releases/press-releases/2026/FDA-Approves-New-Guardant360-Liquid-CDx-the-Largest-FDA-Approved-Liquid-Biopsy-Panel-with-a-100x-Expanded-Footprint/default.aspx

Disclaimer: This article is solely for sharing purposes. In the event that it involves issues such as copyright, please contact us promptly, and we will make corrections without delay. Thank you!